Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Multiplicom Appoints Board Chairman

Published: Thursday, June 27, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Appointment of Dr Ian Gilham as Chairman of the Board of Directors.

Multiplicom NV has announced that Dr Ian Gilham has been appointed as Chairman of the Board of Directors.

"We are delighted that Ian has decided to join our team, strengthening the Board at this important time in the company’s development” said Dirk Pollet CEO of Multiplicom.

Pollet continued, “Ian has worked with many companies providing them with valuable experience in research, development and the commercialization of products. We look forward to working with him and have every confidence that his expertise will help us grow the company and deliver value for both new and existing investors.”

Dr. Gilham was Chief Executive Officer of Axis-Shield plc, a public in-vitro diagnostics company, until Alere acquired it in November 2011.

Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008.

Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogenetic tests, as well as novel diagnostic tests used in targeting GSK’s medicines.

Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of clinical diagnostics and pharmaceuticals.

Commenting on his appointment, Dr Ian Gilham said: “It is with great pleasure that I have accepted the opportunity to become Chairman to the Board of Multiplicom. The molecular diagnostics market is undergoing rapid growth, fuelled by the decreasing cost of DNA sequencing and increased availability of genetic information that links genes to health and disease. The outlook is very promising for the genomic and somatic mutations that Multiplicom is focused on. I look forward to working with the Board to make sure the company fulfills its clearly evident potential.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Multiplicom’s BRCA MASTR™ Dx Test Accredited with CE/IVD Mark
BRCA MASTR Dx will be shipped throughout Europe from September 2012.
Wednesday, June 20, 2012
Multiplicom Receives €200,000 Grant for Novel Non-Invasive Pre-Natal Test
IWT grant to support development of early aneuploidy detection during pregnancy.
Thursday, June 07, 2012
Scientific News
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Antibiotic Susceptibility Testing
A team of biologists and biomedical researchers at UC San Diego has developed a new method to determine if bacteria are susceptible to antibiotics within a few hours, an advance that could slow the appearance of drug resistance and allow doctors to more rapidly identify the appropriate treatment for patients with life threatening bacterial infections.
Spotlight on Acoustic Liquid Handling
Journal of Laboratory Automation special issue highlights how acoustic liquid handling enables breakthrough innovations.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!